Merck KGaA withdraws Erbitux NSCLC filing
This article was originally published in Scrip
Executive Summary
Merck KGaA has decided to voluntarily withdraw its marketing authorisation application (MAA) to the European Medicines Agency (EMA) for a label extension for Erbitux (cetuximab) in non-small cell lung cancer (NSCLC).